Get started
MODERNA, INCMODERNA, INCMODERNA, INC

MODERNA, INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MRNA trade ideas

$MRNA to $90-115 | 100-150% upside in FY 2025- NASDAQ:MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco. - This company is beaten down to the ground and has low market cap as compared to other biopharma stocks. - 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth. - Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
NASDAQ:MRNALong
by bigbull037
$MRNA has 50-100% upside from $43 in FY 2025- NASDAQ:MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research. - NASDAQ:MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term. - In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year. - Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
NASDAQ:MRNALong
by bigbull037
6
Moderna (MRNA) Down 92% from All-Time High – What's Next?Overview: Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower? Key Insights: Support Levels: Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area. Catalysts to Watch: Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
NASDAQ:MRNA
by SpokoStocks
The Share Price of Moderna (MRNA) Surged Over 10% in a DayThe Share Price of Moderna (MRNA) Surged Over 10% in a Day As shown by the chart of pharmaceutical company Moderna (MRNA): → 2024 was an extremely difficult year, with the price falling by approximately 60%; → however, in early 2025, we can see signs of renewed strength. During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America. This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials. Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action. Additionally: → there has been a breakout above the descending trend channel that dominated the end of 2024; → it is possible that price movements may form a new ascending channel (shown in blue); → further growth may be hindered by the psychological resistance level of $50. According to TipRanks, analysts remain cautious about Moderna’s prospects: → only 4 out of 19 analysts recommend buying MRNA shares; → the average 12-month price target for MRNA is $62. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NASDAQ:MRNA
by FXOpen
2
Halftime Update: MRNA - Moderna AnalysisMRNA is currently retesting a pivotal level of resistance that we believe could provide a greater push back to those higher $58.55 Price Levels as long as it can keep this momentum that it has, seeing a very large volume spike in this morning. If not, we would expect some consolidation back to $45.42 levels before pushing higher. Stock jumped this morning after reporting a potential vaccine to combat the recent H5N1 Bird Flu. This comes after the first human death due to the Bird Flu in Louisiana, although the patient did have pre-existing medical conditions that contributed to the death, not to stir any feathers. Don't really have a price projection or entry specifically for this as we're watching. This could pull back to those EMAs before gaining True Momentum Northward. Connect with us by visiting the website below in our signature to get even more at @MyMIWallet #MyMIWallet
NASDAQ:MRNALong
by MyMIWallet
Moderna (MRNA): mRNA Leader Trading at a 90% Discount1️⃣ mRNA Technology Leadership: Moderna is revolutionizing vaccine development with its cutting-edge mRNA platform, positioning itself as a leader in the future of healthcare innovation. 2️⃣ Analyst Targets: With 28 ratings averaging $71.40 and highs of $85, Moderna offers over 60% upside from current levels. 3️⃣ Expanding Pipeline: Moderna’s broadening pipeline includes a variety of treatments, giving it multiple high-growth opportunities in the healthcare sector. 4️⃣ Technical Momentum: Moderna is holding key support at $43.85, with bullish signals of upward movement. The stock is primed for a breakout, supported by increasing volume and positive market sentiment. 📈 Trade Setup: 🎯 Take Profit 1: $50 (+14% potential gain) 🎯 Take Profit 2: $60 (+37% potential gain) 🏆 Take Profit 3: $70 (+59% potential gain) 📉 Stop Loss: $35 ⚠️ (For those with a conservative risk profile, but not necessary for long-term holders like myself)
NASDAQ:MRNALong
by ValchevFinance
1
MRNA Moderna Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought MRNA on the recent breakout: My price target for MRNA in 2025 is $55, driven by the following fundamental factors: Innovative mRNA Technology and Expanding Pipeline: Moderna has established itself as a leader in mRNA technology, initially gaining prominence through its COVID-19 vaccine. The company is now leveraging this innovative platform to develop a diverse array of therapeutic candidates, with approximately 40 development projects in progress across various fields, including infectious diseases, oncology, and rare genetic disorders. This broad pipeline not only enhances Moderna's potential for future revenue but also positions it to capitalize on emerging healthcare needs as the demand for advanced therapies continues to rise. Projected Revenue Growth: Despite facing financial challenges, including recent losses, Moderna's revenue outlook remains promising. The company is forecasting sales between $2.5 billion and $3.5 billion for 2025, which analysts believe could be conservative given the anticipated rollout of new vaccines and treatments. If successful, these products could significantly boost sales and profitability, driving investor confidence and stock price appreciation 16. Market projections suggest that if Moderna successfully navigates its clinical trials and product launches, the stock could reach around $80 per share by 2025. Strategic Partnerships and Collaborations: Moderna's strategic collaborations with major pharmaceutical companies enhance its development capabilities and market access. These partnerships are crucial for accelerating product development and increasing the adoption of its mRNA technology across various therapeutic areas. By aligning with established players in the industry, Moderna can leverage additional resources and expertise to bring its innovations to market more effectively. Market Sentiment and Recovery Potential: Currently trading at lower valuations due to past performance fluctuations, Moderna's stock is positioned for recovery as investor sentiment shifts with positive developments in its pipeline. The company's five-year growth trajectory shows resilience despite recent setbacks, indicating potential for a rebound as new products come to market. Analysts remain optimistic about Moderna's long-term prospects, suggesting that as the market recognizes the value of its innovative therapies, the stock could see substantial gains.
NASDAQ:MRNALong
by TopgOptions
3
MODERNA (MRNA) BULLISH IN SEVERAL WAYS. I'M GOING LONGModerna has recently broken out of the downtrend line of the past 6 months. It has also formed a cup and handle with a double bottom of support. MRNA closed Friday, Dec. 6th, 2024 above both its' 8 Day EMA and its' 21 Day EMA. RSI is rising and about to cross the centerline. I predict the stock will continue to work its' way back up to the $118 level over the next 6 months, where it will meet significant resistance due to overhead supply. Thanks
NASDAQ:MRNALong
by jtcaston
2